journal article·2018-10-31Open access

Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells

Shaojia Wen, Xun Wang, Yamin Wang, Jianfeng Shen, Junyi Pu, Hui Liang, Chao Chen, Linna Liu, Penggao Dai

Abstract

Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. 5-fluorouracil (5-FU)-based chemotherapeutic regimens are routinely used for the treatment of patients with CRC. However, recurrence and chemotherapeutic drug resistance limit the survival rates of patients with CRC. DNA methylation participates in diverse cellular processes by regulating the transcription of a large number of genes expression, cell division, apoptosis, cell adhesion and differentiation, and metabolism, thus it might mediate chemoresistance. Using an Illumina Infinium HD Assay, DNA methylation levels in a human 5-FU-resistant HCT-8 CRC cell line (HCT-8/FU) and its progenitor cell line HCT-8 were analysed. A total of 16,580 differentially methylated genes were identified, of which 8885 were hypermethylated and 7695 were hypomethylated in resistant cells. Among these genes, NME2 (nucleoside diphosphate kinase 2) exhibited a significant difference in methylation between cell lines and has known roles in gastric cancer and breast cancer; accordingly, we hypothesized that it plays a role in acquired resistance in CRC. Knockdown of NME2 restored 5-FU sensitivity in 5-FU-resistant CRC cells, reduced cell survival and increased cell apoptosis; and overexpression of NME2 in HCT-8 cells results in the acquisition of resistance to 5-FU, this alteration enhanced HCT-8 cells growth abilities and reduced apoptosis. These findings suggest that NME2 mediates chemoresistance to 5-FU in CRC and that specific NME2 inhibition could optimize 5-FU-based chemotherapy of CRC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Mechanisms of cancer metastasis · Metastasis and carcinoma case studies · Chromatin Remodeling and Cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Life Science, Northwest University

Pharmacy Department, Tangdu Hospital, Fourth Military Medical University

Funding

National Natural Science Foundation of China

References (35)

Show source-provided references
1. 10.3322/caac.2120810.3322/caac.21208 ↗
2. 10.1016/j.ccr.2013.05.01410.1016/j.ccr.2013.05.014 ↗
3. 10.1186/1741-7015-12-310.1186/1741-7015-12-3 ↗
4. Velde CJHVD, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum . Eur J Cancer. 2014;50:1.e1–1e.34.
5. 10.1038/nbt.168510.1038/nbt.1685 ↗
6. 10.1016/j.fct.2017.07.02210.1016/j.fct.2017.07.022 ↗
7. 10.1038/nrg327010.1038/nrg3270 ↗
8. 10.1186/1471-2407-13-28010.1186/1471-2407-13-280 ↗
9. 10.1093/annonc/mdt41010.1093/annonc/mdt410 ↗
10. 10.1093/jjco/hyr08110.1093/jjco/hyr081 ↗
11. 10.1016/0016-5085(94)90748-X10.1016/0016-5085(94)90748-X ↗
12. 10.1371/journal.pone.010259010.1371/journal.pone.0102590 ↗
13. 10.1007/s11010-009-0120-710.1007/s11010-009-0120-7 ↗
14. Stahl JA, Leone A, Rosengard AM, et al. Identification of a second human nm23 gene, nm23-H2. Cancer Res. 1991;51:445.
15. 10.1038/sj.onc.120525910.1038/sj.onc.1205259 ↗
16. Flørenes VA, Aamdal S, Myklebost O, et al. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992;52:6088–6091.
17. 10.1053/hupa.2000.823010.1053/hupa.2000.8230 ↗
18. Leone A, Seeger RC, Hong CM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene. 1993;8:855–865.
19. Iizuka N, Oka M, Noma T, et al. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res. 1995;55:652–657.
20. 10.1016/j.cell.2010.03.02010.1016/j.cell.2010.03.020 ↗
21. 10.1016/S1470-2045(11)70335-710.1016/S1470-2045(11)70335-7 ↗
22. 10.1371/journal.pone.005576110.1371/journal.pone.0055761 ↗
23. Liu Y, Yang A, Wei L, et al. NME2 reduces proliferation, migration and invasion of gastric cancer cells to limit metastasis. PLoS One. 2015;10:e0115968.10.1371/journal.pone.0115968 ↗
24. 10.1158/1078-0432.CCR-04-125810.1158/1078-0432.CCR-04-1258 ↗
25. Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 1994;54:1825.
26. 10.1016/j.cell.2012.08.03310.1016/j.cell.2012.08.033 ↗
27. 10.1016/j.gde.2009.11.00110.1016/j.gde.2009.11.001 ↗
28. 10.1101/gad.106700310.1101/gad.1067003 ↗
29. Berberich SJ, Postel EH. PuF/NM23-H2/NDPK-B transactivates a human c-myc promoter-CAT gene via a functional nuclease hypersensitive element. Oncogene. 1995;10:2343–2347.
30. 10.1093/nar/gkn91910.1093/nar/gkn919 ↗
31. 10.1073/pnas.170266311410.1073/pnas.1702663114 ↗
32. 10.1021/bi049136q10.1021/bi049136q ↗
33. 10.1248/bpb.b15-0017610.1248/bpb.b15-00176 ↗
34. 10.1097/FPC.0b013e328341db0510.1097/FPC.0b013e328341db05 ↗
35. Shen H, Xu J, Zhao S, et al. ShRNA-mediated silencing of the RFC3 gene suppress ovarian tumor cells proliferation. Int J Clin Exp Pathol. 2015;8:8968–8975.